Compass Pathways to participate in three investor conferences in September
August 28, 2024 06:00 ET
|
Compass Pathways
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference
August 06, 2024 08:00 ET
|
Compass Pathways
LONDON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways announces second quarter 2024 financial results and business highlights
August 01, 2024 06:30 ET
|
Compass Pathways
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori...
Compass Pathways to announce second quarter financial results on August 1, 2024
July 24, 2024 07:01 ET
|
Compass Pathways
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways appoints Lori Englebert as Chief Commercial Officer
June 26, 2024 06:30 ET
|
Compass Pathways
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key...
Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 24, 2024 16:01 ET
|
Compass Pathways
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
May 08, 2024 06:45 ET
|
Compass Pathways
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces...
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
May 08, 2024 06:30 ET
|
Compass Pathways
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5...
Compass Pathways to announce first quarter financial results on May 8, 2024
May 03, 2024 16:58 ET
|
Compass Pathways
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
May 02, 2024 06:30 ET
|
Compass Pathways; Mindful Health Solutions
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...